Literature DB >> 31478104

The association between genotypes of urate transporter-1, Serum uric acid, and mortality in the community-based population: the Yamagata (Takahata) Study.

Soichiro Kon1, Tsuneo Konta2, Kazunobu Ichikawa1, Masafumi Watanabe1, Hidenori Sato3, Kenichi Ishizawa3, Yoshiyuki Ueno3, Hidetoshi Yamashita3, Takamasa Kayama3.   

Abstract

BACKGROUND: The urate transporter-1 (URAT1) is crucial in developing hyperuricemia via reabsorption of uric acid in renal tubules, and its function is regulated by several single nucleotide polymorphisms (SNPs) within SLC22A12 gene encoding URAT1. This study investigated whether the genetic predisposition of URAT1 is associated with the mortality in general population.
METHODS: This study enrolled 1596 participants (male 45%, mean age 61 years) who registered at local health checkup in Takahata, Japan, and the association between the rs505802 genotypes in SLC22A12 gene and the 7-year mortality, was examined.
RESULTS: The serum uric acid levels (mean ± SD) at baseline in the subjects with GG and AG + AA genotypes of rs505802 were 5.1 ± 1.3 mg/dL and 5.0 ± 1.5 mg/dL, respectively. Kaplan-Meier analysis revealed that the mortality was nonsignificantly higher in the subjects with GG genotype than in those with AG + AA genotype (P = 0.09). Cox proportional hazard model adjusted with age, gender, renal function, comorbidities, and other possible confounders, demonstrated that the GG genotype was significantly associated with the mortality [hazard ratio (HR) 2.23, 95% confidence interval (CI) 1.05-4.85, (vs. AG + AA genotype)]. Furthermore, adjustment with serum uric acid levels, along with aforementioned confounders retained the significant association (HR 2.26, 95% CI 1.05-4.85).
CONCLUSIONS: This study revealed that the genetic predisposition of URAT1 was independently associated with mortality in the Japanese community-based population. This association might be due to the mechanism independent of serum uric acid levels.

Entities:  

Keywords:  Mortality; SLC22A12; Snps; URAT1; Uric acid

Mesh:

Substances:

Year:  2019        PMID: 31478104     DOI: 10.1007/s10157-019-01781-y

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  24 in total

1.  Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Authors:  Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

Review 2.  Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?

Authors:  Sofia G Tsouli; Evangelos N Liberopoulos; Dimitri P Mikhailidis; Vasilios G Athyros; Moses S Elisaf
Journal:  Metabolism       Date:  2006-10       Impact factor: 8.694

3.  Serum uric acid in relation to age and physique in health and in coronary heart disease.

Authors:  M M GERTLER; S M GARN; S A LEVINE
Journal:  Ann Intern Med       Date:  1951-06       Impact factor: 25.391

4.  Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk.

Authors:  Hung-Pin Tu; Chia-Min Chung; Albert Min-Shan Ko; Su-Shin Lee; Han-Ming Lai; Chien-Hung Lee; Chung-Ming Huang; Chiu-Shong Liu; Ying-Chin Ko
Journal:  J Hum Genet       Date:  2016-05-26       Impact factor: 3.172

5.  Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.

Authors:  Hirotaka Matsuo; Tappei Takada; Kimiyoshi Ichida; Takahiro Nakamura; Akiyoshi Nakayama; Yuki Ikebuchi; Kousei Ito; Yasuyoshi Kusanagi; Toshinori Chiba; Shin Tadokoro; Yuzo Takada; Yuji Oikawa; Hiroki Inoue; Koji Suzuki; Rieko Okada; Junichiro Nishiyama; Hideharu Domoto; Satoru Watanabe; Masanori Fujita; Yuji Morimoto; Mariko Naito; Kazuko Nishio; Asahi Hishida; Kenji Wakai; Yatami Asai; Kazuki Niwa; Keiko Kamakura; Shigeaki Nonoyama; Yutaka Sakurai; Tatsuo Hosoya; Yoshikatsu Kanai; Hiroshi Suzuki; Nobuyuki Hamajima; Nariyoshi Shinomiya
Journal:  Sci Transl Med       Date:  2009-11-04       Impact factor: 17.956

6.  Albuminuria is an independent predictor of all-cause and cardiovascular mortality in the Japanese population: the Takahata study.

Authors:  Tsuneo Konta; Kosuke Kudo; Hiroko Sato; Kazunobu Ichikawa; Ami Ikeda; Kazuko Suzuki; Atsushi Hirayama; Yoko Shibata; Tetsu Watanabe; Makoto Daimon; Takeo Kato; Yoshiyuki Ueno; Takamasa Kayama; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2013-01-24       Impact factor: 2.801

7.  Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study.

Authors:  Keita Kamei; Tsuneo Konta; Kazunobu Ichikawa; Hiroko Sato; Natsuko Suzuki; Asami Kabasawa; Kazuko Suzuki; Atsushi Hirayama; Yoko Shibata; Tetsu Watanabe; Takeo Kato; Yoshiyuki Ueno; Takamasa Kayama; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2016-01-16       Impact factor: 2.801

8.  Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study.

Authors:  Tsuneo Konta; Mitsuru Emi; Sayumi Toriyama; Hideto Ariumi; Miho Ishii; Satoshi Takasaki; Ami Ikeda; Kazunobu Ichikawa; Yoko Shibata; Noriaki Takabatake; Yasuchika Takeishi; Takeo Kato; Sumio Kawata; Isao Kubota
Journal:  J Hum Genet       Date:  2008-01-24       Impact factor: 3.172

Review 9.  Uric acid and cardiovascular risk.

Authors:  Daniel I Feig; Duk-Hee Kang; Richard J Johnson
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects.

Authors:  Tanya J Flynn; Amanda Phipps-Green; Jade E Hollis-Moffatt; Marilyn E Merriman; Ruth Topless; Grant Montgomery; Brett Chapman; Lisa K Stamp; Nicola Dalbeth; Tony R Merriman
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.